AIM ImmunoTech gets safety committee nod for Phase 2 of Ampligen + Imfinzi in pancreatic cancer

AIM ImmunoTech Inc.

Safety committee approved Phase 2 based on Phase 1 data: no severe adverse events or dose-limiting toxicities.
Phase 2 enrollment expected to commence imminently; up to 25 patients to be enrolled.
Combination therapy uses AIM's Ampligen and AstraZeneca's Imfinzi for late-stage pancreatic cancer.
Phase 1 data showed combination generally well-tolerated; some patients had stable disease for 15+ months.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.